Synthesis of novel triplet drugs with 1,3,5-trioxazatriquinane skeletons and their pharmacologies. 1: Synthesis of triplet drugs with morphinan skeletons.

[1]  P. Portoghese,et al.  A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm. , 2011, ACS medicinal chemistry letters.

[2]  K. Palczewski.  Oligomeric forms of G protein-coupled receptors (GPCRs). , 2010, Trends in biochemical sciences.

[3]  H. Nagase,et al.  Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration. , 2010, Bioorganic & medicinal chemistry letters.

[4]  L. Miller,et al.  Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization. , 2010, Journal of medicinal chemistry.

[5]  M. Waldhoer,et al.  Opioid-receptor-heteromer-specific trafficking and pharmacology. , 2010, Current opinion in pharmacology.

[6]  H. Nagase,et al.  Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative. , 2009, Bioorganic & medicinal chemistry.

[7]  H. Mochizuki,et al.  Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. , 2009, Drugs of today.

[8]  H. Nagase,et al.  Novel synthesis of a 1,3,5-trioxazatriquinane skeleton using a nitrogen clamp. , 2009, Organic letters.

[9]  M. Narita,et al.  Synthesis of novel twin drug consisting of 8-oxaendoethanotetrahydromorphides with a 1,4-dioxane spacer and its pharmacological activities: mu, kappa, and putative epsilon opioid receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[10]  H. Nagase,et al.  Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists. , 2008, Bioorganic & medicinal chemistry.

[11]  H. Nagase,et al.  Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. , 2008, Bioorganic & medicinal chemistry letters.

[12]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[13]  C. Hague,et al.  Heterodimerization of G Protein-Coupled Receptors: Specificity and Functional Significance , 2005, Pharmacological Reviews.

[14]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[15]  B. O'dowd,et al.  Oligomerization of opioid receptors: generation of novel signaling units. , 2002, Current opinion in pharmacology.

[16]  L. Devi,et al.  G-protein-coupled receptor dimerization: modulation of receptor function. , 2001, Pharmacology & therapeutics.

[17]  H. Nagase,et al.  Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. , 1998, Chemical & pharmaceutical bulletin.

[18]  F. Gibson,et al.  The structure of enterochelin and related 2,3-dihydroxy-N-benzoylserine conjugates from Escherichia coli. , 1970, Biochimica et biophysica acta.

[19]  J. Neilands,et al.  Enterobactin, an iron transport compound from Salmonella typhimurium. , 1970, Biochemical and biophysical research communications.

[20]  H. Nagase,et al.  Synthesis of novel basic skeletons derived from naltrexone. , 2011, Topics in current chemistry.

[21]  H. Fujii.  Twin and triplet drugs in opioid research. , 2011, Topics in current chemistry.

[22]  H. Brockmann,et al.  Valinomycin I, XXVII. Mitteil. über Antibiotica aus Actinomyceten , 1955 .